NO984881D0 - Oralt farmas°ytisk preparat inneholdende ibandronat - Google Patents

Oralt farmas°ytisk preparat inneholdende ibandronat

Info

Publication number
NO984881D0
NO984881D0 NO984881A NO984881A NO984881D0 NO 984881 D0 NO984881 D0 NO 984881D0 NO 984881 A NO984881 A NO 984881A NO 984881 A NO984881 A NO 984881A NO 984881 D0 NO984881 D0 NO 984881D0
Authority
NO
Norway
Prior art keywords
preparation containing
oral pharmaceutical
surface preparation
containing ibandronate
pharmaceutical surface
Prior art date
Application number
NO984881A
Other languages
English (en)
Other versions
NO984881L (no
NO319162B1 (no
Inventor
Ckel J Rn M
Rolf-Dieter Gabel
Heinrich Woog
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7791961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO984881(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of NO984881D0 publication Critical patent/NO984881D0/no
Publication of NO984881L publication Critical patent/NO984881L/no
Publication of NO319162B1 publication Critical patent/NO319162B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
NO19984881A 1996-04-20 1998-10-19 Oral, farmasoytisk utleveringsform inneholdende ibandronattil behandling av bensykdommer NO319162B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19615812A DE19615812A1 (de) 1996-04-20 1996-04-20 Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
PCT/EP1997/001940 WO1997039755A1 (de) 1996-04-20 1997-04-21 Orale pharmazeutische zubereitung enthaltend ibandronat

Publications (3)

Publication Number Publication Date
NO984881D0 true NO984881D0 (no) 1998-10-19
NO984881L NO984881L (no) 1998-10-19
NO319162B1 NO319162B1 (no) 2005-06-27

Family

ID=7791961

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19984881A NO319162B1 (no) 1996-04-20 1998-10-19 Oral, farmasoytisk utleveringsform inneholdende ibandronattil behandling av bensykdommer

Country Status (26)

Country Link
US (2) US6143326A (no)
EP (2) EP0936913B2 (no)
JP (2) JP5037746B2 (no)
CN (1) CN101152160A (no)
AR (2) AR006652A1 (no)
AT (1) ATE404207T1 (no)
AU (1) AU722516B2 (no)
BR (1) BR9708785A (no)
CA (1) CA2251886C (no)
CO (1) CO4820394A1 (no)
CZ (1) CZ297341B6 (no)
DE (2) DE19615812A1 (no)
DK (1) DK0936913T4 (no)
ES (1) ES2313735T5 (no)
HU (1) HU228389B1 (no)
IL (2) IL126655A (no)
NO (1) NO319162B1 (no)
NZ (1) NZ332314A (no)
PA (1) PA8427301A1 (no)
PL (2) PL191910B1 (no)
PT (1) PT936913E (no)
RU (1) RU2193881C2 (no)
SI (1) SI0936913T2 (no)
TR (1) TR199802108T2 (no)
WO (1) WO1997039755A1 (no)
ZA (1) ZA973331B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
IL133405A0 (en) * 1997-06-11 2001-04-30 Procter & Gamble Film-coated tablet for improved upper gastrointestinal tract safety
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
CN1224423C (zh) * 2000-07-17 2005-10-26 山之内制药株式会社 改善口服吸收的医药组合物
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
EP1228761A3 (en) * 2001-02-01 2003-01-15 Riderway Corporation Liquid pharmaceutical composition for treating bone diseases
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
WO2003055496A1 (en) * 2001-12-21 2003-07-10 The Procter & Gamble Company Method for the treatment of bone disorders
NZ535456A (en) 2002-02-21 2006-08-31 Biovail Lab Int Srl Modified release formulations of at least one form of tramadol for oral administration
KR20120065435A (ko) 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
BR0309691A (pt) * 2002-12-20 2005-08-02 Hoffmann La Roche Formulação de ibandronato em alta dose
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
CA2646334A1 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
CN101495101B (zh) * 2006-07-25 2012-02-29 兴和株式会社 糖衣制剂及其制造方法
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
WO2009075601A1 (fr) * 2007-12-12 2009-06-18 Alexander Valerievich Melnik Moyen d'indication d'une éventuelle prédisposition de chats à une maladie (variantes) et procédé de détermination de troubles de la santé chez les chats
EP2210596A1 (en) * 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
CN103079596B (zh) 2010-08-31 2015-08-19 东丽株式会社 药物固体制剂用的包衣剂、药物用膜制剂以及包覆药物固体制剂
CN103501767A (zh) * 2011-06-17 2014-01-08 赢创罗姆有限公司 适合于药物或营养制品剂型的包衣组合物
RU2485957C1 (ru) * 2012-03-16 2013-06-27 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия последипломного образования" Министерства здравоохранения Российской Федерации (ГБОУ ДПО РМАПО Минздрава России) Средство для лечения низкообменного варианта заболевания скелета у больных с хронической почечной недостаточностью

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE965825C (de) 1949-10-30 1957-06-19 Walter Kloepfer Dipl Ing Dr In Zur Antennenebene senkrecht polarisierter Strahler
US4820698A (en) * 1985-11-04 1989-04-11 The Procter & Gamble Company Antimicrobial agents and process for their manufacture
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5098717A (en) * 1987-12-09 1992-03-24 Thames Pharmacal Co., Inc. Method of treatment for pruritus
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
TW237386B (no) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
HU220872B1 (en) * 1993-05-15 2002-06-29 Roche Diagnostics Gmbh Tablets containing dichloromethylene diphosphonic acid as active agent with enhanced bioavailability and process for producing them
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US5803321A (en) * 1996-11-12 1998-09-08 Randy Hangers, Lll Hanger with ganging element
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
ZA973331B (en) 1998-10-19
AU2638297A (en) 1997-11-12
DE19615812A1 (de) 1997-10-23
SI0936913T1 (sl) 2008-12-31
CZ297341B6 (cs) 2006-11-15
EP1658852B1 (de) 2016-11-09
CA2251886C (en) 2008-06-17
AU722516B2 (en) 2000-08-03
WO1997039755A1 (de) 1997-10-30
HU228389B1 (en) 2013-03-28
JP5037746B2 (ja) 2012-10-03
JP2000508673A (ja) 2000-07-11
PL329347A1 (en) 1999-03-29
ES2313735T5 (es) 2012-12-07
US20050089573A1 (en) 2005-04-28
US6143326A (en) 2000-11-07
RU2193881C2 (ru) 2002-12-10
CO4820394A1 (es) 1999-07-28
IL163930A0 (en) 2005-12-18
SI0936913T2 (sl) 2012-11-30
ATE404207T1 (de) 2008-08-15
EP0936913B1 (de) 2008-08-13
AR054350A2 (es) 2007-06-20
TR199802108T2 (xx) 1999-01-18
DK0936913T4 (da) 2012-11-19
JP5557989B2 (ja) 2014-07-23
JP2008285500A (ja) 2008-11-27
CA2251886A1 (en) 1997-10-30
DK0936913T3 (da) 2008-10-20
PL191363B1 (pl) 2006-05-31
PT936913E (pt) 2008-09-25
PA8427301A1 (es) 2002-07-30
BR9708785A (pt) 1999-08-03
PL191910B1 (pl) 2006-07-31
EP1658852A1 (de) 2006-05-24
EP0936913B2 (de) 2012-09-19
IL126655A (en) 2004-12-15
DE59712959D1 (de) 2008-09-25
NZ332314A (en) 2000-03-27
AR006652A1 (es) 1999-09-08
NO984881L (no) 1998-10-19
HUP9903407A3 (en) 2000-11-28
IL126655A0 (en) 1999-08-17
NO319162B1 (no) 2005-06-27
CN101152160A (zh) 2008-04-02
EP0936913A1 (de) 1999-08-25
ES2313735T3 (es) 2009-03-01
HUP9903407A2 (hu) 2000-04-28
CZ336498A3 (cs) 2000-01-12

Similar Documents

Publication Publication Date Title
NO984881D0 (no) Oralt farmas°ytisk preparat inneholdende ibandronat
NO20001612L (no) Oralt preparat
ATE265850T1 (de) Ibuprofenhaltige arzneizubereitung
NO973612L (no) Nytt farmasöytisk preparat
EE200000383A (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
FI973749A0 (fi) Suun kautta annosteltava 2-metyylitienobentsodiatsepiinivalmiste
NO963032D0 (no) Oralt preparat
NO992339D0 (no) Farmas°ytiske formuleringer
NO20005399D0 (no) Farmasøytisk preparat
NO996372L (no) Fast farmasøytisk preparat inneholdende benzofuanderivater
DK1466615T3 (da) Farmaceutisk præparat
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
ATE223705T1 (de) Rapamycin enthaltende formulierungen zur oralen verabreichung
NO990707D0 (no) Farmas°ytisk preparat inneholdende 4-oksobutansyrer
EE9800400A (et) Diklofenaaki sisaldavad farmatseutilised kompositsioonid
NO995039D0 (no) Gastrisk bibeholdt farmasöytisk preparat
NO973610D0 (no) Nytt farmasöytisk preparat
DE69827947D1 (de) Rapamycin-formulierungen zur oralen verabreichung
ID30032A (id) Formulasi farmasi
NO992999D0 (no) Farmas°ytisk blanding for oral administrering
NO973611D0 (no) Nytt farmasöytisk preparat
NO950950D0 (no) Farmasöytisk preparat
NO20003284L (no) Farmasøytisk preparat for oral administrering
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
SE9803952D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
MK1K Patent expired